Skip to main content

On This Page

← AI Financial News

Dave Inc. – 2026-01-14 - Increase Confidence 8/10

2 min read $DAVE
Share

These articles are AI-generated summaries. Please check the original sources for full details.

DAVEDave Inc.
$211.72-4.53 (-2.09%)
$256$219$183Oct 14Nov 26Jan 13
52W High: $256.0552W Low: $182.51Volume: 476.00K
NasdaqGM
Prediction (1/28/2026):High: $286.45Low: $65.46Ref Price: $185.46
This chart shows historical data as of January 13, 2026. Not updated in real-time.

DAVE – Increase in Days/Weeks

Dave Inc. reported a 64% year-over-year revenue surge to $131.7M in Q2 2025, accompanied by a 236% jump in adjusted EBITDA, signaling accelerating profitability. This fundamental momentum is reinforced by the recent upgrade to CashAI v5.5, which is expected to reduce delinquency and boost lending margins.

Why This Matters

The combination of robust top-line growth, expanding profitability, and operational improvements via AI-driven underwriting indicates that Dave is transitioning into a more sustainable growth phase—just as investor sentiment appears poised for a rebound despite recent price weakness. With the stock trading well below the $306.4 average analyst price target, current levels reflect excessive pessimism relative to the company’s improving financial trajectory.

Key Insights

  • Revenue & Profitability: Revenue (TTM) now $491.3M, net income (TTM) $146.73M, reflecting strong execution and margin expansion.
  • News Impact: CashAI v5.5 rollout and $125M expanded buyback signal confidence in future cash flows and credit quality.
  • Risk/Offset: High debt/equity (25.85) and beta (3.91) increase volatility, while bearish options positioning suggests near-term skepticism.

Practical Implications

  • Bull Case: Earnings momentum and buyback execution could drive a re-rating toward $230+ in 2–3 weeks.
  • Bear Case: Macro risk or credit deterioration could trigger a test of $170 support, exacerbated by high beta.
  • Confidence: 8/10 – Strong fundamentals and catalysts outweigh near-term sentiment risks.

Prediction: increase

Reference:

Continue reading

Next article

Edgewise Therapeutics – 2026-01-14 - Increase Confidence 8/10

Related Content